Takeda

We follow the science, to unlock innovation and pursue sustainable answers. We are guided by our commitment to patients, our people and the planet. Our vision is to deliver life-transforming treatments to those in need. We are steadfast in our purpose for better health for people and a brighter future for the world.

We leave the #IFPAConference2024 inspired by the resilience of those in the psoriasis and psoriatic arthritis communities. Our dedication to making a difference in patients’ lives is stronger than ever. Thank you to IFPA for bringing the community together for this incredible event. This information is for IFPA conference attendees only. It should never be used as a substitute for the advice provided by your healthcare provider. Please consult with your healthcare provider for medical advice. Takeda does not have any approved treatment for psoriasis or psoriatic arthritis.

We are pleased to announce the publication of our 2024 Annual Integrated Report (AIR). This year’s report highlights how we are tackling meaningful challenges – from advancing equitable access to health care to protecting people and communities from the impacts of climate change — together with our partners. Our sustainability approach is rooted in three corporate philosophy imperatives: Patient, People, and Planet, enabled by data, digital and technology. And this year, we highlighted the following five stories that demonstrate our value creation: - Sustainable value creation in Plasma-Derived Therapies business - Our patient-centric approach to drug development - Creating positive impact for healthcare and climate resilience - Easing the burden of Inflammatory Bowel Disease (IBD) - Focus on our Vienna and Los Angeles sites as they celebrate seven decades of serving global & community needs We hope you find this year’s AIR to be an insightful guide to understanding our efforts and achievements. Click the link to read the full report: https://lnkd.in/e5mjr8G7

Chronic inflammatory demyelinating polyneuropathy (CIDP) is a progressive motor and/or sensory neurologic condition that affects peripheral nerves. CIDP is frequently underdiagnosed, misdiagnosed, or overdiagnosed, which can lead to a significant delay in appropriate diagnosis and treatment of the disease. Join our esteemed faculty in Helsinki – including Professors Johannes Jakobsen, Vera Bril and Claudia Sommer – today for an interactive symposium where audience members will vote on specific CIDP patient cases to discuss diagnosis and appropriate management plans. #EAN2024

We’re excited to be at #EAN2024 to share results today from the Takeda-funded research illustrating the relationship between patient burden and disease severity in #Narcolepsy and #IdiopathicHypersomnia. This is one of the largest studies to date on the burden of illness in these diseases. The findings strengthen our resolve to address the significant unmet needs in sleep-wake disorders and enhance the lives of those affected by these neurological conditions. Be sure to join us for this oral presentation on Monday, July 1st at 18:45 EEST in room #OPR105

Our ambition is to have unprecedented patient diversity in our Phase 3 psoriasis trials. We are working with community-based organizations toward a goal of understanding the needs of diverse communities. Read the full story: https://lnkd.in/eWT7NbYq This information is not intended to substitute consultation with a healthcare provider. If you or a loved one are concerned about psoriasis, please consult with your healthcare professional. Takeda does not have any approved treatment for psoriasis.

We are working with community-based organizations toward a goal of understanding the needs of diverse communities so that more people of color feel comfortable talking to their doctor about participation in psoriasis clinical trials. Read the full story: https://lnkd.in/eVHdwggC This information is not intended to substitute consultation with a healthcare provider. If you or a loved one are concerned about psoriasis, please consult with your healthcare professional. Takeda does not have any approved treatment for psoriasis.

In a Q&A with Clinical Leader, Elena Koundourakis, head of the Orexin franchise development and neuroscience portfolio strategy, explains why Takeda is exploring the use of digital health tools with Beacon Biosignals to support future clinical development and diagnosis of narcolepsy. Read more here: https://lnkd.in/eVQb-Fer #WhereScienceis #WhereScienceIsDigital

"Takeda is welcoming, has good practices and makes me feel free to be who I am," shares Sales Representative Aline Chinelatto. Throughout Pride Month and beyond, our Takeda Resource Group (TRG) Take Pride empowers employees globally. Take Pride leaders and members uphold our commitment to diversity, equity and inclusion, advocating for the LGBTQ+ community and creating a more inclusive workplace by identifying and addressing potential barriers to inclusion. Learn more about Take Pride: https://lnkd.in/eiYmJSVk #PrideMonth #Belonging

We are thrilled to celebrate 10 years of the European Academy of Neurology Congress (#EAN2024), to engage with the scientific community and share insights from our research. Neurological diseases can alter our ability to think, sleep, remember, and move independently. Our vision is to be a leader and partner in neuroscience by creating life-transforming medicines for people and society. We are proud to share our findings and eager to learn more about the latest scientific advances across neurology. If you’re a healthcare professional planning to attend, be sure to visit Takeda at booth #E54. We look forward to seeing you there.